Advances in the therapeutic management of hepatocellular carcinoma (HCC) have created new opportunities to optimize patient outcomes and care. Join expert Richard S. Finn, MD, and his colleagues as they address key clinical considerations through patient case stories, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management.
7:00 PM: Welcome and Introduction
7:05 PM: CaseBook 1: Optimizing Treatment Selection for Newly Diagnosed Patients With Advanced HCC Richard S. Finn, MD
7:25 PM: CaseBook 2: Enhancing Sequencing Strategies With Second-Line Targeted Agents, Immunotherapy, and Combinations Robin K. (“Katie”) Kelley, MD
7:45 PM: Case Book 3: Improving Outcomes With Emerging Strategies Across the HCC Continuum Laura M. Kulik, MD
8:00 PM: Adjourn
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with hepatocellular carcinoma (HCC).
Upon completion of this activity, participants should be better able to:
- Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC
- Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting
- Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum
- Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients’ needs
This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This accredited CME/MOC activity has been developed in collaboration with Blue Faery: The Adrienne Wilson Liver Cancer Association.
This educational activity is supported by independent medical education grants through AstraZeneca, Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., Genentech, and Merck & Co., Inc.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California
Robin K. (“Katie”) Kelley, MD
San Francisco, California
Laura M. Kulik, MD
Northwestern University Feinberg School of Medicine
Chicago, Illinois
The Medical Learning Institute, Inc. (MLI) requires faculty, planners, staff, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they, and their spouse/life partners, may have as related to the content of this activity. These disclosures will be provided to learners prior to the start of the activity. All identified COI are thoroughly vetted and resolved according to MLI policy. MLI is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com. *Please note that if you are requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number & DOB (MM/DD). A score of 70% or higher is needed to obtain MOC credit.
Copyright © 2000-2020, PeerView